Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,263 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,110 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,003)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02826486 | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients(COMBAT) | completed | Phase 2 | 80 | BioLineRx, Ltd.INDUSTRY | 4 |
| Aug 28, 2024 |
| clinicaltrials |
| NCT01752933 | SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 52 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT02873195 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 133 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT03981614 | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | completed | Phase 2 | 102 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05086627 | Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer | completed | Phase 2 | 118 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02743221 | A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy(TASCO1) | completed | Phase 2 | 154 | Institut de Recherches Internationales ServierOTHER | 12 | Aug 20, 2024 | clinicaltrials |
| NCT04228601 | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 39 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT01595321 | Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas | completed | Phase 2 | 19 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05662527 | Response to Immunotherapy in MMR-deficient Localized Colon Cancer(RESET-C) | completed | Phase 2 | 85 | Camilla QvortrupOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03647969 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | completed | Phase 2 | 262 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT00788957 | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | completed | Phase 1 / Phase 2 | 177 | NantBioScience, Inc.INDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT03190265 | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | completed | Phase 2 | 61 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT03852251 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | completed | Phase 1 / Phase 2 | 338 | AkesoINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03490292 | Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer | completed | Phase 1 / Phase 2 | 22 | University of Wisconsin, MadisonOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02697058 | Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer | completed | Phase 2 | 84 | Institut de Recherches Internationales ServierOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03274882 | Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies | completed | Phase 2 | 26 | Institut de Recherches Internationales ServierOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | completed | Phase 2 | 120 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT03336216 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 205 | Bristol-Myers SquibbINDUSTRY | 11 | Jul 23, 2024 | clinicaltrials |
| NCT00891930 | Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | completed | Phase 2 | 74 | NantBioScience, Inc.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT02352337 | First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem(PANOPTIMOX) | completed | Phase 2 | 276 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02827201 | FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine(FIRGEMAX) | completed | Phase 2 | 127 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03510871 | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 43 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04839471 | BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)(BEAR) | completed | Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04435197 | Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma(PALACE-2) | completed | Phase 2 | 143 | Ruijin HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04677504 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | completed | Phase 2 | 162 | Hoffmann-La RocheINDUSTRY | 13 | Jul 3, 2024 | clinicaltrials |
| NCT03921021 | Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | completed | Phase 2 | 17 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04518852 | TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | completed | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04919642 | Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma | completed | Phase 2 | 55 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03077685 | Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 54 | NanOlogy, LLCINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT05518071 | FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1(FLUOPANC) | completed | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT03217643 | CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.(EATL-001) | completed | Phase 2 | 14 | Imagine InstituteOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04808791 | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 7 | AHS Cancer Control AlbertaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06454071 | Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients | completed | Phase 2 | 75 | Soonchunhyang University HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03382600 | Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) | completed | Phase 2 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT06232759 | TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 56 | Guangxi Medical UniversityOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02834052 | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | completed | Phase 1 / Phase 2 | 42 | Asha NayakOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT01580397 | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | completed | Phase 2 | 15 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04172571 | A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 31 | AkesoINDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT04256980 | Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement | completed | Phase 2 | 34 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT04842565 | cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria | completed | Phase 2 | 20 | Fudan UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04207918 | A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer | completed | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT02746796 | Study of ONO-4538 in Gastric Cancer | completed | Phase 2 / Phase 3 | 680 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 3, 2024 | clinicaltrials |
| NCT04216251 | PRevention Using EPA Against coloREctal Cancer(PREPARE) | completed | Phase 1 / Phase 2 | 81 | Massachusetts General HospitalOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03146962 | High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies | completed | Phase 2 | 61 | Weill Medical College of Cornell UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT03165994 | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | completed | Phase 2 | 34 | Apexigen America, Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 28, 2024source: clinicaltrials